Innate Pharma (IPHA) Asset Utilization Ratio (2022 - 2025)
Innate Pharma's (IPHA) quarterly Asset Utilization Ratio came in at 0.91 in Q4 2025, up 10.4% YoY from 0.83 in Q4 2024, and up 10.4% on a QoQ basis from 0.83 in Q4 2024.
Innate Pharma (IPHA) Asset Utilization Ratio (2022 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 4 years of Asset Utilization Ratio data on file, last reported at 0.91 in Q4 2025.
- Quarterly Asset Utilization Ratio rose 10.4% year-over-year to 0.91 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.91 (up 10.4% YoY) and the FY2025 annual result came in at 0.11, down 21.88% from the prior year.
- Asset Utilization Ratio advanced to 0.91 in Q4 2025, from 0.83 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 288.29 in Q2 2024 to a low of 0.06 in Q2 2022.
- A 4-year average of 140.52 and a median of 201.93 in 2022 frame the typical range for Asset Utilization Ratio.
- Annual changes were most pronounced in 2023 — Asset Utilization Ratio surged 393355.94% — and 2024, when it sank 99.67%.
- Tracing IPHA's Asset Utilization Ratio over 4 years: stood at 201.93 in 2022, then rose by 23.9% to 250.18 in 2023, then sank by 99.67% to 0.83 in 2024, then grew by 10.4% to 0.91 in 2025.
- The last three Asset Utilization Ratio figures came in at 0.91 (Q4 2025), 0.83 (Q4 2024), and 288.29 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 0.90 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.13 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.54 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.13 |
| 10 | Innate Pharma | 202.03 Mn | 202.03 Mn | - | 0.91 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.91 |
| Dec 31, 2024 | 0.83 |
| Jun 30, 2024 | 288.29 |
| Dec 31, 2023 | 250.18 |
| Jun 30, 2023 | 241.40 |
| Dec 31, 2022 | 201.93 |
| Jun 30, 2022 | 0.06 |